ORETON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oreton, and when can generic versions of Oreton launch?
Oreton is a drug marketed by Schering and is included in two NDAs.
The generic ingredient in ORETON is methyltestosterone. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oreton
A generic version of ORETON was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORETON?
- What are the global sales for ORETON?
- What is Average Wholesale Price for ORETON?
Summary for ORETON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 63 |
| Patent Applications: | 4,602 |
| DailyMed Link: | ORETON at DailyMed |
US Patents and Regulatory Information for ORETON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | ORETON | methyltestosterone | TABLET;BUCCAL | 080281-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Schering | ORETON METHYL | methyltestosterone | TABLET;ORAL | 003158-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Schering | ORETON METHYL | methyltestosterone | TABLET;ORAL | 003158-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
